Related Experiment Video
Updated: Jun 26, 2026
05:16
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
Defining an evidence-based cutpoint for medication adherence in heart failure
Jia-Rong Wu1, Debra K Moser, Marla J De Jong
1University of Kentucky, College of Nursing, Lexington, 40536-0232, USA. jiarongwu@uky.edu
American Heart Journal
|February 3, 2009
Summary
Achieving 88% medication adherence in heart failure patients significantly improves event-free survival. This evidence-based cutpoint aids clinicians in optimizing patient outcomes and treatment strategies.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Research
Background:
- Medication adherence is crucial for heart failure management.
- Clinically relevant adherence thresholds linked to outcomes remain undefined.
Purpose of the Study:
- To identify the specific medication adherence level associated with improved event-free survival in heart failure patients.
- To establish an evidence-based cutpoint for optimal adherence.
Main Methods:
- Longitudinal study of 135 heart failure patients over 3.5 years.
- Objective adherence measurement using the Medication Event Monitoring System (MEMS) assessing dose count and dose days.
- Statistical analyses included Kaplan-Meier plots, Cox regression, and ROC curves.
Main Results:
- Event-free survival was significantly better at adherence levels of 88% or higher for both dose count and dose days.
- An 88% adherence cutpoint demonstrated optimal sensitivity and specificity in predicting outcomes.
- Nonadherence below 88% increased the hazard ratio for adverse events (HR=2.2 for dose count, HR=3.2 for dose days).
Conclusions:
- An adherence level of 88% is recommended for optimal clinical outcomes in heart failure.
- This study provides a critical evidence-based threshold for medication adherence.
- Findings support clinicians and researchers in setting adherence targets for improved heart failure management.
Related Concept Videos
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Heart Failure VII: Nursing Interventions
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:28Mitral Regurgitation IV: Nursing Management
Mitral regurgitation (MR) is a condition where the mitral valve does not close properly, leading to the backward flow of blood from the left ventricle into the left atrium during systole. This condition can arise from various causes, including rheumatic fever, infective endocarditis, or degenerative valve disease. Effective nursing management is crucial to optimizing patient outcomes and involves comprehensive assessment and targeted interventions.Comprehensive Patient AssessmentA detailed...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...